Nutriband Files Patent to Extend AVERSA Abuse-Deterrent Tech Protection

Nutriband Inc. (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, has taken a significant step in strengthening its intellectual property portfolio by filing a provisional patent application with the U.S. Patent and Trademark Office. This filing aims to expand protection for the company's innovative AVERSA™ abuse-deterrent transdermal technology, covering improved aversive formulations and advanced coating application methods designed to enhance abuse deterrence and increase resistance to tampering. The strategic move could potentially extend AVERSA's market protection by up to 20 years from the filing date if successfully converted to a non-provisional patent and granted by regulatory authorities. This development builds upon AVERSA's existing global patent protection across 46 countries, positioning Nutriband as a key player in the critical field of pharmaceutical safety technology.

The company's lead product under development is an abuse-deterrent fentanyl patch that incorporates this groundbreaking AVERSA™ technology, which represents a crucial advancement in addressing the ongoing opioid crisis. The technology's unique approach involves incorporating aversive agents directly into transdermal patches to prevent misuse, diversion, and accidental exposure of drugs with abuse potential while maintaining therapeutic accessibility for legitimate patients who require these medications. For investors and stakeholders seeking comprehensive information, the company maintains detailed updates through its InvestorBrandNetwork presence and corporate website at www.nutriband.com. The patent filing represents a significant milestone in Nutriband's corporate strategy to establish itself as a leader in pharmaceutical safety innovation, particularly in the high-stakes area of controlled substance delivery systems where abuse prevention has become a public health priority.

This announcement was distributed through InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio that provides advanced wire-grade press release syndication and comprehensive corporate communications solutions. The platform's extensive reach ensures that this important development receives appropriate visibility among investors, healthcare professionals, and industry stakeholders who recognize the critical importance of abuse-deterrent technologies in modern pharmaceutical development. The enhanced patent protection strategy demonstrates Nutriband's commitment to maintaining its competitive edge in the rapidly evolving pharmaceutical safety landscape, where technological innovation plays an increasingly vital role in balancing patient access with public safety concerns.